<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109680</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ 92579-1048-0</org_study_id>
    <nct_id>NCT01109680</nct_id>
  </id_info>
  <brief_title>A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects</brief_title>
  <official_title>A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <brief_summary>
    <textblock>
      A Single Center, Open-Label Study to quantify metabolites of [14C]-Neramexane in plasma and&#xD;
      urine in Healthy Male Subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolite Profiling</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Metabolism of Neramexane</condition>
  <arm_group>
    <arm_group_label>14 C labelled Neramexane, capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neramexane</intervention_name>
    <description>Multiple dose Neramexane followed by single dose 14C Neramexane</description>
    <arm_group_label>14 C labelled Neramexane, capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 55 to 65 years inclusive&#xD;
&#xD;
          -  BMI of 18-29 kg/m2 (inclusive) and a body weight of ≥50 and ≤90 kg&#xD;
&#xD;
          -  All ethnicities, Fitzpatrick type &lt; IV (see appendix 2)&#xD;
&#xD;
          -  Willing and able to provide written informed consent after having been informed of the&#xD;
             requirements and the restrictions of the study&#xD;
&#xD;
          -  Healthy adult male subject, who is able to read, to write and fully understand Dutch&#xD;
             language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically relevant allergy or known hypersensitivity to&#xD;
             Neramexane/Memantine/Amantadine and their derivates&#xD;
&#xD;
          -  Exposure to another investigational agent within the last two months before first drug&#xD;
             administration&#xD;
&#xD;
          -  Administration of radiolabeled substance or exposure to significant radiation (e.g.&#xD;
             serial X-ray or CT scans etc.) within the last 12 months. X-rays or spiral CT scans of&#xD;
             extremities are allowed.&#xD;
&#xD;
        Lack of suitability for the study&#xD;
&#xD;
          -  Any evidence of a significant cardiovascular, pulmonary, renal, hepatic,&#xD;
             gastrointestinal, endocrinological, metabolic, psychiatric, neurologic or other acute&#xD;
             or chronic disease&#xD;
&#xD;
          -  Disorders or surgery of the gastrointestinal tract which may interfere with drug&#xD;
             absorption or may otherwise influence the pharmacokinetics of the investigational&#xD;
             medicinal products (e.g. cholecystectomy, active gastric ulcers, etc.)&#xD;
&#xD;
          -  Clinically relevant acute or chronic infections, observed within 4 weeks before first&#xD;
             drug administration&#xD;
&#xD;
          -  History of malignancy, except basal cell carcinoma&#xD;
&#xD;
          -  Any clinically relevant deviation in clinical or laboratory assessment as deemed by&#xD;
             the investigator&#xD;
&#xD;
          -  Abnormalities in the 12-lead ECG (at screening) which in the discretion of the&#xD;
             investigator and the Merz scientific expert are clinical relevant or might affect the&#xD;
             study objectives&#xD;
&#xD;
          -  Systolic blood pressure &lt;95 mmHg or &gt;155 mmHg or diastolic blood pressure &lt; 50 mmHg or&#xD;
             &gt;95 mmHg in supine position&#xD;
&#xD;
          -  Pulse rate &lt;45 or &gt;100 beats per minute&#xD;
&#xD;
          -  History of alcohol or drug dependence&#xD;
&#xD;
          -  Alcohol consumption averaging a weekly intake in excess of 21 units of alcohol (one&#xD;
             unit of alcohol equals a glass of beer of 300 mL, a glass of wine of 125 mL, or a&#xD;
             measure of spirits of 25 mL) within the last year&#xD;
&#xD;
          -  Regular large caffeine consumption averaging more than 6 cups of coffee and/or tea per&#xD;
             day or more than 1 L of caffeine-containing beverages per day within the last year&#xD;
&#xD;
          -  Use of any prescribed medication 4 weeks prior to the first administration of IMP&#xD;
             (except paracetamol, maximum 2 g/day). Thyroid hormone substitution will be allowed)&#xD;
&#xD;
          -  Regular use of over-the-counter drugs 4 weeks prior to the first administration of the&#xD;
             IMP.&#xD;
&#xD;
          -  Occasional use of OTC drugs (except paracetamol, maximum 2 g/day) in the 2 weeks prior&#xD;
             to the first administration of the IMP&#xD;
&#xD;
          -  Use of any food, food supplement or medication known to induce or inhibit CYP3A4 or&#xD;
             other cytochrome P450 enzymes within two weeks before first drug administration e.g.&#xD;
             grapefruit, St. Johns wort&#xD;
&#xD;
          -  Consume of xanthine derivates (including caffeine) within two days before first drug&#xD;
             administration&#xD;
&#xD;
          -  Smokers or ex-smokers who have stopped for less than 6 months, and user of snuff,&#xD;
             nicotine replacement chewing tobacco&#xD;
&#xD;
          -  Blood donation more than 450 mL within 60 days before first drug administration&#xD;
&#xD;
          -  Positive results in any of the serology tests&#xD;
&#xD;
          -  Positive drug screen or alcohol test&#xD;
&#xD;
          -  Subject is an employee or direct relative of an employee of the CRO or Merz&#xD;
             Pharmaceuticals&#xD;
&#xD;
          -  Lack of ability or willingness to give informed consent&#xD;
&#xD;
          -  Lack of willingness or inability to co-operate adequately&#xD;
&#xD;
          -  Vulnerable subjects (e.g. persons kept in detention)&#xD;
&#xD;
          -  Anticipated non-availability for study visits/procedures&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SGS Life Science Services</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>April 22, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <last_update_submitted>February 7, 2011</last_update_submitted>
  <last_update_submitted_qc>February 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Dirk Garmann</name_title>
    <organization>Merz Pharmaceuticals GmbH</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

